Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PTEN dec exp |
Therapy | Pemetrexed Disodium + Sorafenib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN dec exp | Advanced Solid Tumor | predicted - sensitive | Pemetrexed Disodium + Sorafenib | Phase I | Actionable | In a Phase I clinical trial, low Pten expression or lack of Pten expression was associated with better response to treatment with the combination of Alimta (pemetrexed) and Nexavar (sorafenib) in patients with advanced solid tumors (PMID: 27213589). | 27213589 |
PubMed Id | Reference Title | Details |
---|---|---|
(27213589) | Phase I study of pemetrexed with sorafenib in advanced solid tumors. | Full reference... |